ROBERT KRANCE to Immunophenotyping
This is a "connection" page, showing publications ROBERT KRANCE has written about Immunophenotyping.
Connection Strength
0.107
-
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
Score: 0.025
-
t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia. Leukemia. 1992 Apr; 6(4):251-5.
Score: 0.022
-
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
Score: 0.015
-
Acute megakaryoblastic leukemia in children and adolescents: a retrospective analysis of 24 cases. Leuk Lymphoma. 1993 Jul; 10(4-5):299-306.
Score: 0.012
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.009
-
XYY syndrome in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1997 Jan; 28(1):6-8.
Score: 0.008
-
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993 Jan 09; 341(8837):85-6.
Score: 0.006
-
Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 1992 Dec 15; 80(12):3182-8.
Score: 0.006
-
Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. Leukemia. 1992; 6 Suppl 2:162-6.
Score: 0.005